Abstract
Herein, the synthesis and biological evaluation of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole sulfonamide hybrids are discussed. All the synthesized molecules were assessed for anti-cancer and anti-TB activities using in vitro and in silico methods. The molecular docking study with CDK8 as a possible target for anti-cancer activity demonstrated that compounds 2, 3, 5, 7, 8, and 9 have a good binding affinity ranging from −8.7 to −10.3 kcal/mol against CDK8 (PDB 6T41) protein as compared with the standard drug 5-Fluorouracil (−5.0 kcal/mol). The in vitro anti-mycobacterial screening reveals that compounds 2 and 3 elicited moderate anti-TB activity with a MIC value of 25 µM. Compounds 2 and 3 exhibited moderate in vitro anti-proliferative potency against the cancer cell lines MCF-7 and HCT-116. Moreover, compound 3 exhibited a better anti-oxidant effect among all tested compounds. Some quantum chemical parameters and drug-likeness profiling of the molecules were modeled by density functional theory (DFT) and ADME studies. The obtained theoretical results are in good agreement with the experimental results.
Acknowledgment
The authors are thankful to Dr. Vagolu Siva Krishna, Department of Microbiology, University of Oslo (Norway) for providing biological activity support.
Disclosure statement
No potential conflict of interest was reported by the author(s).